Células T CAR: Proeza que traspasa los avances en el tratamiento de las hemopatías malignas

Lina María Martínez-Sánchez, Luis Felipe Álvarez-Hernández, Mariana Roldán-Isaza

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

Resumen

Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment. Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses . Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes. Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine.

Título traducido de la contribuciónCar T cells: Progress that passes the advances in the treatment of malignant hemopathies
Idioma originalEspañol
Páginas (desde-hasta)41-50
Número de páginas10
PublicaciónRevista Cubana de Hematologia, Inmunologia y Hemoterapia
Volumen34
N.º4
EstadoPublicada - 1 oct. 2018
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2018, Editorial Ciencias Medicas. All rights reserved.

Palabras clave

  • CAR T
  • Genetic engineering
  • Immunotherapy
  • Lymphoma
  • T-lymphocytes

Huella

Profundice en los temas de investigación de 'Células T CAR: Proeza que traspasa los avances en el tratamiento de las hemopatías malignas'. En conjunto forman una huella única.

Citar esto